Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

New approach shows promise in fighting multiple cancers

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor's cancerous cells influence their surroundings, blocking the body's immune defenses and creating a sort of haven in which the tumor can grow. Treatments that target some of these pro-tumor actions are effective in a number of cancers, but only for some patients; in others, these treatments have little effect.

17 Jan 2025

Targeting tertiary lymphoid structures for cancer treatment

A research team at Memorial Sloan Kettering Cancer Center (MSK) has made new insights into how the body forms immune cell clusters called tertiary lymphoid structures (TLSs) in response to foreign threats such as cancer.

16 Jan 2025

Pancreatic cancer insights: How pORG classifications predict survival and guide treatment

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

15 Jan 2025

Researchers uncover new mutation mechanism driving cancer progression

Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a significant impact on young people and their families as treatment can require surgery or amputation.

15 Jan 2025

Experimental blood test for pancreatic cancer moves closer to real-world use

An experimental blood test for pancreatic cancer that was developed by Van Andel Institute and University of Pittsburgh scientists is being evaluated by a commercial laboratory, an important milestone toward making the test available for patients.

13 Jan 2025

MICAL2 enzyme found to promote tumor growth in pancreatic cancer

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective treatment options for the disease.

2 Jan 2025

New molecular imaging agent can accurately identify crucial cancer biomarker

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer.

18 Dec 2024

DTI detects precancerous lesions in the pancreas

Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreiro – respectively head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Centre's Radiology Department – have shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancreas.

13 Dec 2024

Deep learning transforms PDAC diagnosis and treatment

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using histopathology images.

13 Dec 2024

Pioneering study discovers new genetic links to pancreatic cancer in Brazil

Pancreatic cancer has recently been included in the list of diseases about which Brazil's National Cancer Institute (INCA) periodically publishes statistics.

9 Dec 2024

Experts gather at NCCN summit to promote patient-centered cancer information

The National Comprehensive Cancer Network (NCCN) - a non-profit alliance of leading cancer centers - hosted a Patient Advocacy Summit in Washington, D.C., today.

6 Dec 2024

Study uncovers mechanism behind nutrient scavenging in pancreatic cancer

Cancer cells are like booming cities without urban planners. They expand quickly, and in doing so, the resulting tumors consume more energy and other resources than they can acquire from nearby blood vessels.

6 Dec 2024

p53 mutations show diverse impact on pancreatic cancer metabolism

A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas.

6 Dec 2024

New collaborative effort aims to cure ALK-positive lung cancer

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year.

6 Dec 2024

Report highlights increasing use of targeted therapies before surgery for cancer treatment

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person's survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) Cancer Programs.

3 Dec 2024

University of Oklahoma professor honored with prestigious Palade Prize for pancreatic cancer research

Min Li, Ph.D., a George Lynn Cross Professor of Medicine, Surgery and Cell Biology at the University of Oklahoma College of Medicine and Associate Director for Global Oncology at OU Health Stephenson Cancer Center, will receive the 2024 Palade Prize from the International Association of Pancreatology.

26 Nov 2024

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.

19 Nov 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

New drug strategy reverses resistance to immunotherapy in pancreatic cancer

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and Oregon Health & Science University.

14 Nov 2024

Study highlights air pollution as key environmental factor in autism risk

Air pollution is a key environmental risk factor for autism, influencing neurodevelopment through neuroinflammation, oxidative stress, and epigenetic changes.

14 Nov 2024